Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices

EXCLI Journal

Volumn 11, Issue , 2012, Pages 142-149

  Sakthiswary, R ^a   Syahrul Sazliyana, S ^a   Mohd Shahrir, M S ^a   Shahril, N S ^b   Hussein, H ^b  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b PUTRAJAYA HOSPITAL   (Malaysia)

Author keywords

Adalimumab; Anemia; Lipid profile; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SCREENING; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LIPID ANALYSIS; MALAYSIA; MALE; OUTCOME ASSESSMENT; REMISSION; RHEUMATOID ARTHRITIS;

EID: 84867620646     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D. Effects of repeated inflixi-mab therapy on serum lipid profile in pa-tients with refractory rheumatoid arthritis. Clin Chim Acta 2006;365:143-8.
2. Ballantyne FC, Fleck A, Dick WC. Albumin metabolism in rheumatoid arthritis. Ann Rheum Dis 1971;30:265-70.
3. Boyer GS, Templin DW, Lanier AP. Rheu-matic diseases in Alaskan Indians of the southeast coast: high prevalence of rheuma-toid arthritis and systemic lupus erythemato-sus. J Rheumatol 1991;18:1477-84.
4. Brekke OH, Sandlie I. Therapeutic antibod-ies for human diseases at the dawn of the twenty-first century. Nature RevDrug Dis-cov 2003;2:52-62.
5. Buck I, Morceau F, Grigorakaki C, Dicato M, Diederich M. Linking anemia to inflam-mation and cancer: the crucial role of TNF-alpha. Biochem Pharmacol 2009;77:1572-9.
6. Chen X, Xun K, Chen L, Wang Y. TNF-alpha, a potent lipid metabolism regulator. Cell Biochem Function 2009;27:407-16.
7. DeRienzo DP, Saleem A. Anemia of chronic disease: a review of pathogenesis. Texas Medicine 1990;86(10):80-3.
8. Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO 3rd et al. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, ran-domized clinical trials. Semin Arthrit Rheum 2009;39:123-31.
9. McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A et al. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTER-HEART Modifiable Risk Score. Eur Heart J 2011;32:581-9.
10. Mehran M, Seidman E, Marchand R, Gurbindo C, Levy E. Tumor necrosis factor-alpha inhibits lipid and lipoprotein transport by Caco-2 cells. Am J Physiol 1995;269: G953-60.
11. Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plas-ma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci 2010;10:248-52.
12. Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in pa-tients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5.
13. Riazzoli J, Nilsson JA, Teleman A, Peters-son IF, Rantapaa-Dahlqvist S, Jacobsson LT et al. Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level. Rheumatology 2010;49:2098-103.
14. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O. Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a comparison of a large cohort to the world's literature. J Clin Laboratory Analysis 1999;13:280-6.
15. Rubin DT, Mulani P, Chao J, Pollack PF, Bensimon AG, Yu AP et al. Effect of ada-limumab on clinical laboratory parameters in patients with Crohn's disease: Results from the CHARM trial. Inflamm Bowel Dis 2011 Sep 1. doi: 10.1002/ibd.21836. [Epub ahead of print].
16. Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-alpha treat-ment on lipid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 2006;1069:414-9.
17. Soubrier M, Jouanel P, Mathieu S, Poujol D, Claus D, Dubost JJ et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint, bone, spine. Rev Rhumatisme 2008;75:22-4.
18. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990;49:665-7.
19. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE et al. Efficacy, pharmacokinetic, and safety as-sessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal an-tibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Therapeut 2003;25:1700-21.
20. Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes EG, Kastelein JJ et al. Sustained changes in lipid profile and mac-rophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1316-21.